Friday, July 10, 2026

Drug profile · INN

betibeglogene autotemcel

betibeglogene autotemcel (ZYNTEGLO) is a hemoglobin beta chain exogenous gene.

EMA: withdrawn Blood and blood forming organs (B06) B06A
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — betibeglogene autotemcel
Class
Blood and blood forming organs (B06)
Route
Patents
0
Programs
0
Data quality
0.83

Quick answer

betibeglogene autotemcel (ZYNTEGLO) is a hemoglobin beta chain exogenous gene.

Key facts

INN betibeglogene autotemcel
Brand ZYNTEGLO
Mechanism Hemoglobin beta chain exogenous gene
Target Hemoglobin subunit beta
Therapeutic class Blood and blood forming organs (B06)
ATC code B06A

Mechanism of action

Hemoglobin beta chain exogenous gene

Primary target: Hemoglobin subunit beta

Approval history

Authority Status Date
EMA withdrawn

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Frequently asked questions

What is betibeglogene autotemcel?

betibeglogene autotemcel (ZYNTEGLO) is a hemoglobin beta chain exogenous gene.

What is the brand name for betibeglogene autotemcel?

ZYNTEGLO is a marketed brand name for betibeglogene autotemcel. Check FDA Drugs@FDA for the current US label holder and prescribing information.